Approved TE BsAbs include the mouse/rat chimeric Triomab catumaxomab (EpCAM × CD3), an orphan drug for Epidermal Cell Adhesion Molecule (EpCAM)-positive malignant ascites, and the tandem single chain variable fragment (scFv) bispecific T cell engaging (BiTE) antibody blinatumomab (CD3 × CD19) for refractory Philadelphia chromosome-negative acute lymphoblastic leukemia [30] (Table 3). The gene discussed is EPCAM; the disease is acute lymphoblastic leukemia.